COLL - コレギウム・ファ―マシュ―ティカル (Collegium Pharmaceutical Inc.)

COLLのニュース

   Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference  2021/09/13 12:00:00 Intrado Digital Media
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting data regarding its product portfolio were presented at the Annual PAINWeek National Conference, which took place September 7-11, 2021 in Las Vegas, NV.
   Collegium to Participate in Upcoming Investor Conferences  2021/09/01 20:01:00 Intrado Digital Media
STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences during the month of September:
   Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2021 Results - Earnings Call Transcript  2021/08/07 19:27:06 Seeking Alpha
   Collegium Stock Is Getting Beaten As Q2 Earnings Miss Street Estimates; Revises FY21 Guidance  2021/08/06 16:21:40 Business Insider Markets
Collegium Pharmaceutical Inc (NASDAQ: COLL ) reported Q2 adjusted EPS of $0.27, below the consensus of $0.36.
   Collegium Pharmaceutical, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/06 14:37:19 Seeking Alpha
   Collegium Pharmaceutical Inc (COLL) falls -1.8060% for June 17 - Equities News  2021/06/22 11:12:27 Equities
Collegium Pharmaceutical Inc (COLL) falls -1.8060% for June 17 Equities.com
   Collegium Announces Publication of Real-World Data in Journal of Pain Research  2021/06/16 20:01:00 Benzinga
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL ), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, "Nonmedical Use of Xtampza ® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-world Data from the Addiction Severity Index Multimedia Version (ASI-MV ® )," was published in the peer-reviewed medical journal, Journal of Pain Research . "An important part of our commitment to responsible pain management includes ongoing surveillance of real-world data assessing the incidence of abuse, misuse and diversion related to our product portfolio," said Richard Malamut, M.D., Executive Vice President and Chief Medical Officer of Collegium. "We will continue to support the analysis and publication of real-world data as it becomes available. We believe it is important for the medical and scientific communities to have access to these data to inform treatment decisions when prescribing effective analgesic therapy to treat people suffering from pain." While the analysis reported in this publication contributes to an understanding of the relative rates of nonmedical use of various opioid products, nothing in the findings should be construed as suggesting that Xtampza ER (oxycodone) extended-release capsules, does not have a high potential for addiction, abuse, or misuse.
   Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL)  2021/05/28 13:15:12 Smarter Analyst
Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $34.00. The post Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
   Collegium to Participate in Upcoming Investor Conference - May 20, 2021  2021/05/20 00:00:00 BioSpace
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conference
   Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL)  2021/05/14 13:55:31 Smarter Analyst
In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL), with a price target of $34.00. The post Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
   Collegium Announces Publication of Real-World Data in Journal of Pain Research  2021/06/16 20:01:00 Benzinga
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL ), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, "Nonmedical Use of Xtampza ® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-world Data from the Addiction Severity Index Multimedia Version (ASI-MV ® )," was published in the peer-reviewed medical journal, Journal of Pain Research . "An important part of our commitment to responsible pain management includes ongoing surveillance of real-world data assessing the incidence of abuse, misuse and diversion related to our product portfolio," said Richard Malamut, M.D., Executive Vice President and Chief Medical Officer of Collegium. "We will continue to support the analysis and publication of real-world data as it becomes available. We believe it is important for the medical and scientific communities to have access to these data to inform treatment decisions when prescribing effective analgesic therapy to treat people suffering from pain." While the analysis reported in this publication contributes to an understanding of the relative rates of nonmedical use of various opioid products, nothing in the findings should be construed as suggesting that Xtampza ER (oxycodone) extended-release capsules, does not have a high potential for addiction, abuse, or misuse.
   Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL)  2021/05/28 13:15:12 Smarter Analyst
Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $34.00. The post Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
   Collegium to Participate in Upcoming Investor Conference - May 20, 2021  2021/05/20 00:00:00 BioSpace
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conference
   Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL)  2021/05/14 13:55:31 Smarter Analyst
In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL), with a price target of $34.00. The post Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .

calendar